Key result
Sacubitril-valsartan gradually improves aortic distensibility and fractional area change over six months in HFrEF patients.
Why the study?
Sacubitril-valsartan has not been thoroughly investigated to determine its effects on vascular function and structure in patients with HFrEF.
Does sacubitril-valsartan improve aortic distensibility and fractional area change measured by echocardiography in patients with HFrEF?
Does sacubitril-valsartan improve aortic distensibility and fractional area change measured by echocardiography in patients with HFrEF?
Sacubitril-valsartan may improve vascular stiffness parameters (aortic distensibility and fractional area change) in HFrEF patients over six months, as measurable by echocardiography.
May suggest vascular benefits of sacubitril-valsartan in HFrEF; hypothesis-generating and requires randomized validation.
Background: Heart failure with reduced ejection fraction (HFrEF) people are exposed to increased risk of death that can be predicted by several factors, one of which is increased vascular stiffness. Sacubitril-valsartan has not been thoroughly investigated in this population to determine its effects on vascular function and structure. Based on the vasodilatory features of sacubitril–valsartan, we expected that fractional area change (AFAC) as well as aortic distensibility (AD), when measured through 2D transthoracic echocardiography (TTE), should enhance with treatment course in HFrEF patients. Objective: This review article aimed to determine whether aortic stiffness can be measured by echocardiography in heart failure patients receiving sacubitril-valsartan medication or not. Methods: Search terms for the study included echocardiography, HFrEF, sacubitril-valsartan, aorta, and entresto in PubMed and Google Scholar. After the writers carefully analysed references from the relevant literature, including all the acknowledged research and reviews, only the most recent or complete studies between February 1995 and July 2021 were included. Since no sources for interpretation could be found, non-English language documents have been ignored. Dissertations, discussions, abstract papers from conferences, and everything else that wasn't a fundamental scientific research had been excluded. Conclusion: The positive benefits of sacubitril–valsartan on AD and AFAC as evaluated by TTE are increasing gradually from baseline to six months.
No takes yet. Share an insight, caveat, or question.
Seaoud et al. (2022) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Sacubitril-valsartan was evaluated on Aortic distensibility (AD) and fractional area change (AFAC) evaluated by TTE. Sacubitril-valsartan treatment in HFrEF patients gradually improves aortic distensibility and fractional area change from baseline to six months as evaluated by transthoracic echocardiography.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: